Maven Securities’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Maven Securities’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-29,000	Closed	-$3.83M	–	1007
2025 Q1	$3.83M	Buy	+29,000	New	+$3.61M	0.12%	163
2022 Q2	–	Sell	-8,919	Closed	-$546K	–	1156
2022 Q1	$546K	Buy	+8,919	New	+$463K	0.02%	516
2021 Q3	–	Sell	-5,100	Closed	-$209K	–	1313
2021 Q2	$209K	Buy	+5,100	New	+$189K	0.01%	933
2021 Q1	–	Sell	-18,342	Closed	-$591K	–	1321
2020 Q4	$591K	Buy	+18,342	New	+$482K	0.06%	325

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Maven Securities's ITCI Position: Q2 2025 in Review

Maven Securities sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 29,000 shares — an estimated $3.83M sold.

Maven Securities first reported a position in ITCI in Q4 2020 and held it in 4 quarters. The position peaked at $3.83M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Maven Securities reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Maven Securities sold 29,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $3.83M.
Maven Securities first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 4 quarters.
Maven Securities's Intra-Cellular Therapies Inc. position peaked at $3.83M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Maven Securities's 13F filing for Q2 2025, filed 14 Aug 2025.